Celiprolol: A Unique Selective Adrenoceptor Modulator

James J. Nawarskas, Angela Cheng-Lai, William H. Frishman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers-Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers-Danlos syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
JournalCardiology in Review
Volume25
Issue number5
DOIs
StatePublished - 2017

Fingerprint

Celiprolol
Adrenergic Receptors
Ehlers-Danlos Syndrome
Blood Vessels
Mechanical Stress
Clinical Pharmacology
Connective Tissue
Antihypertensive Agents
Collagen
Heart Rate
Pressure
Pharmaceutical Preparations

Keywords

  • celiprolol
  • Ehlers-Danlos
  • Ehlers-Danlos syndrome
  • Ehlers-Danlos syndrome type IV
  • vascular Ehlers-Danlos syndrome
  • β-blockers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Celiprolol : A Unique Selective Adrenoceptor Modulator. / Nawarskas, James J.; Cheng-Lai, Angela; Frishman, William H.

In: Cardiology in Review, Vol. 25, No. 5, 2017, p. 247-253.

Research output: Contribution to journalArticle

Nawarskas, James J. ; Cheng-Lai, Angela ; Frishman, William H. / Celiprolol : A Unique Selective Adrenoceptor Modulator. In: Cardiology in Review. 2017 ; Vol. 25, No. 5. pp. 247-253.
@article{e2727d437f554b92b72d114d6357aafa,
title = "Celiprolol: A Unique Selective Adrenoceptor Modulator",
abstract = "Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers-Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers-Danlos syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.",
keywords = "celiprolol, Ehlers-Danlos, Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV, vascular Ehlers-Danlos syndrome, β-blockers",
author = "Nawarskas, {James J.} and Angela Cheng-Lai and Frishman, {William H.}",
year = "2017",
doi = "10.1097/CRD.0000000000000159",
language = "English (US)",
volume = "25",
pages = "247--253",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Celiprolol

T2 - A Unique Selective Adrenoceptor Modulator

AU - Nawarskas, James J.

AU - Cheng-Lai, Angela

AU - Frishman, William H.

PY - 2017

Y1 - 2017

N2 - Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers-Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers-Danlos syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.

AB - Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers-Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers-Danlos syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.

KW - celiprolol

KW - Ehlers-Danlos

KW - Ehlers-Danlos syndrome

KW - Ehlers-Danlos syndrome type IV

KW - vascular Ehlers-Danlos syndrome

KW - β-blockers

UR - http://www.scopus.com/inward/record.url?scp=85028866315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028866315&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000159

DO - 10.1097/CRD.0000000000000159

M3 - Article

C2 - 28742547

AN - SCOPUS:85028866315

VL - 25

SP - 247

EP - 253

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 5

ER -